Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

Expanding Horizons for the Management of Obstructive Hypertrophic Cardiomyopathy: Pharmacist Considerations (Webinar)

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb.

Registration & Dates for Activities

Thurs, Nov 3, 2022
1:00 PM ET Thurs, Nov 10, 2022
3:00 PM ET Tue, Nov 15, 2022
6:00 PM ET

Faculty

Douglas Jennings, Pharm.D., FACC, FAHA, FCCP, FHFSA
Associate Professor of Pharmacy
Clinical Pharmacist, Heart Transplant and LVAD Team
Long Island University Department of Pharmacy Practice
New York-Presbyterian Hospital Columbia University Irving Medical Center
New York, NY

ACCREDITATION STATEMENTS

PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-22-062-L01-P
Credits: 1.0 hours (0.1 ceu)
Estimated time to complete activity: 60 minutes

Location: From the convenience of your home or business; accessible via both PC and MAC
Fee Information: There is no fee for this educational activity.
Type of Activity: Application
Media: Internet

TARGET AUDIENCE

Pharmacists

HOW TO EARN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.

Goal

The goal of these activities is to provide pharmacists with advanced and up-to-date knowledge of the obstructive hypertrophic cardiomyopathy (OHCM) treatment landscape to ensure appropriate access to patient-specific treatments, understanding of therapeutic management and any adverse effects, and enhancing pharmaceutical care, thus leading to improved therapeutic outcomes and quality of life.

LEARNING OBJECTIVES

Upon completion of this activity, the participant should be better able to:

• Explain the pathology, pathophysiology, and epidemiology of hypertrophic cardiomyopathy (HCM) and its subtypes
• Describe the limitations of the current standard of care therapies for obstructive HCM (OHCM)
• Discuss the novel agent, mavacamten, for OHCM and its potential to improve treatment outcomes
• Develop effective approaches to educate patients on the safe and optimal use of the novel agent for OHCM

Agenda

Introduction (5 minutes)
Presentation (45 minutes)
Conclusions & Question & Answer Session (10 minutes)

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5